Source 1review2023Vision Research
Toolkit/retinal prostheses
retinal prostheses
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Additionally, we describe the latest approaches for treatment, including AAV-mediated gene augmentation, genome editing, and late-stage therapies such as optogenetics, cell transplantation, and retinal prostheses.
Usefulness & Problems
Why this is useful
Retinal prostheses are listed as a late-stage therapy discussed in the review. The abstract does not specify device class or implantation approach.; late-stage therapy development for PRPF31-RP; Retinal prostheses are described as a way to artificially stimulate remaining retinal neurons in degenerative blindness.; artificial stimulation of remaining retinal neurons; vision restoration after photoreceptor loss
Source:
Retinal prostheses are listed as a late-stage therapy discussed in the review. The abstract does not specify device class or implantation approach.
Source:
late-stage therapy development for PRPF31-RP
Source:
Retinal prostheses are described as a way to artificially stimulate remaining retinal neurons in degenerative blindness.
Source:
artificial stimulation of remaining retinal neurons
Source:
vision restoration after photoreceptor loss
Problem solved
They are presented as part of the late-stage treatment landscape for PRPF31-RP.; proposed as a late-stage therapeutic approach; It is intended to restore visual input after photoreceptor death.; provides an artificial stimulation strategy for residual retinal circuitry in retinal degeneration
Source:
They are presented as part of the late-stage treatment landscape for PRPF31-RP.
Source:
proposed as a late-stage therapeutic approach
Source:
It is intended to restore visual input after photoreceptor death.
Source:
provides an artificial stimulation strategy for residual retinal circuitry in retinal degeneration
Problem links
proposed as a late-stage therapeutic approach
LiteratureThey are presented as part of the late-stage treatment landscape for PRPF31-RP.
Source:
They are presented as part of the late-stage treatment landscape for PRPF31-RP.
provides an artificial stimulation strategy for residual retinal circuitry in retinal degeneration
LiteratureIt is intended to restore visual input after photoreceptor death.
Source:
It is intended to restore visual input after photoreceptor death.
Published Workflows
Objective: Use PSC-derived retinal models to replicate retinal pathology and enable quantitative assessment for drug discovery, therapy testing, biomarker identification, and toxicity studies while improving physiological relevance and scalability.
Why it works: The review argues that PSCs provide a renewable source for generating retinal tissues suitable for modelling disease and quantitatively evaluating interventions, and that adding automation and more complete multicellular micro-physiological context should improve utility.
generation of light-responsive retinal tissues encompassing all cell typesincorporation of vasculature and immune cells into retinal organoidscapturing interactions between neural retina, RPE, and choriocapillarisPSC differentiationhigh-throughput automationadvanced micro-physiological systems
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
editingInput: Light
Implementation Constraints
cofactor dependency: requires exogenous cofactorencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenimplementation constraint: spectral hardware requirementoperating role: regulator
The abstract does not provide device, surgical, or patient-selection requirements.; The provided abstract only supports that efficacy depends on preserved downstream visual pathway structure and function. It does not specify device class, implantation details, or stimulation hardware.; depends on remaining retinal neurons and downstream visual pathway integrity
The abstract does not suggest that retinal prostheses restore native PRPF31 expression or directly correct the causal genetic defect.; The review states that outcomes remain limited and indicates that prosthetic stimulation does not bypass problems caused by degeneration-related changes in downstream visual pathways.; outcomes have been limited; success depends on morphology, physiology, and proper functioning of intact downstream visual pathway structures
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2022Frontiers in Cellular Neuroscience
Ranked Claims
The review describes treatment approaches for PRPF31-RP including AAV-mediated gene augmentation, genome editing, and late-stage therapies such as optogenetics, cell transplantation, and retinal prostheses.
The success of retinal restoration treatments depends on the morphology, physiology, and proper functioning of remaining intact structures in the downstream visual pathway.
The success of these treatments relies on the morphology, physiology, and proper functioning of the remaining intact structures in the downstream visual pathway.
Alterations that occur in the visual cortex during retinal degeneration are not completely understood.
It is not completely understood what all alterations occur in the visual cortex during RD.
Artificial stimulation strategies for retinal degeneration, including optogenetics, retinal prostheses, and chemical photoswitches, have shown limited outcomes.
Several approaches have been developed in recent years to artificially stimulate the remaining retinal neurons using optogenetics, retinal prostheses, and chemical photoswitches. However, the outcome of these strategies has been limited.
Approval Evidence
2 sources4 linked approval claimsfirst-pass slug retinal-prostheses
Additionally, we describe the latest approaches for treatment, including AAV-mediated gene augmentation, genome editing, and late-stage therapies such as optogenetics, cell transplantation, and retinal prostheses.
Source:
Several approaches have been developed in recent years to artificially stimulate the remaining retinal neurons using optogenetics, retinal prostheses, and chemical photoswitches.
Source:
therapeutic landscape summarysupports
The review describes treatment approaches for PRPF31-RP including AAV-mediated gene augmentation, genome editing, and late-stage therapies such as optogenetics, cell transplantation, and retinal prostheses.
Source:
design constraintsupports
The success of retinal restoration treatments depends on the morphology, physiology, and proper functioning of remaining intact structures in the downstream visual pathway.
The success of these treatments relies on the morphology, physiology, and proper functioning of the remaining intact structures in the downstream visual pathway.
Source:
knowledge gapsupports
Alterations that occur in the visual cortex during retinal degeneration are not completely understood.
It is not completely understood what all alterations occur in the visual cortex during RD.
Source:
review summarysupports
Artificial stimulation strategies for retinal degeneration, including optogenetics, retinal prostheses, and chemical photoswitches, have shown limited outcomes.
Several approaches have been developed in recent years to artificially stimulate the remaining retinal neurons using optogenetics, retinal prostheses, and chemical photoswitches. However, the outcome of these strategies has been limited.
Source:
Comparisons
Source-stated alternatives
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.; The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Source:
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.
Source:
The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Source-backed strengths
positioned as a late-stage treatment option; identified as a developed restoration approach
Source:
positioned as a late-stage treatment option
Source:
identified as a developed restoration approach
Compared with optogenetic functional interrogation
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.; The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: positioned as a late-stage treatment option; identified as a developed restoration approach.
Relative tradeoffs: outcomes have been limited; success depends on morphology, physiology, and proper functioning of intact downstream visual pathway structures.
Source:
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.
Source:
The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Compared with optogenetic membrane potential perturbation
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.; The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: positioned as a late-stage treatment option; identified as a developed restoration approach.
Relative tradeoffs: outcomes have been limited; success depends on morphology, physiology, and proper functioning of intact downstream visual pathway structures.
Source:
The abstract names optogenetics and cell transplantation as other late-stage therapies, and also mentions AAV-mediated gene augmentation and genome editing.
Source:
The abstract names optogenetics and chemical photoswitches as alternative restoration strategies.
Ranked Citations
- 1.
- 2.